GRAPE KING BIO LTD |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 156.5 TWD | +0.32% |
|
+0.97% | +0.32% |
| Feb. 27 | Grape King Bio Ltd Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Jan. 09 | Grape King Bio Hits Record-High Sales of NT$10.64 Billion in 2023 | MT |
ETFs positioned on Grape King Bio Ltd
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.01% | 4 M€ | -4.41% | - | |
| 0.00% | 117 M€ | +1.11% | - | |
| 0.00% | 34 M€ | +2.14% | - |
Grape King Bio Ltd is a Taiwan-based company mainly engaged in the manufacture and sale of healthcare products and beverages. The company operates through three business segments. The Direct Sales segment is engaged in the development and manufacture of related products for subsidiaries. The Distribution segment is engaged in the provision of own-brand products. The Original Equipment Manufacturer (OEM) segment is engaged in the OEM business in Taiwan and Shanghai. The main products include lactic acid bacteria products and other healthcare products, as well as beverage products, medicines and cosmetics. The Company operates in Taiwan, mainland China and other markets.
Sector
Food Processing
Calendar
2024-05-07
- Q1 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
4
Last Close Price
156.5
TWD
Average target price
172.8
TWD
Spread / Average Target
+10.38%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +0.32% | 711M | |
| +8.20% | 7.78B | |
| +10.20% | 6.52B | |
| -8.10% | 3.67B | |
| -13.13% | 3.44B | |
| -14.57% | 1.17B | |
| +8.34% | 934M | |
| -42.27% | 879M | |
| -18.90% | 836M | |
| -16.45% | 802M |
- Stock Market
- Equities
- 1707 Stock
- Funds and ETFs Grape King Bio Ltd
